CareLit Fachartikel

Analysis of the safety profile of the TNF-alpha antibody infliximab based on the pooled data of 3 German post-marketing surveillance studies with 1,075 patients suffering from rhe…

JR Kalden, HP Tony, C Antoni, C Rauch · Zeitschrift für Gastroenterologie · 2004 · Heft 08

Dokument
909100
CareLit-ID
Jahr
2004
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Gastroenterologie
Autor:innen
JR Kalden, HP Tony, C Antoni, C Rauch
Ausgabe
Heft 08 / 2004
Seiten
–
Erschienen: 2004-08-18 00:00:00
ISSN
0044-2771
DOI
10.1055/s-2004-831462

Zusammenfassung

We planned to evaluate the safety profile of the TNF-alpha antagonist infliximab (IFX) in a large population of patients with rheumatoid arthritis (RA) or Crohn's disease (CD) treated with IFX under routine conditions in the post-marketing phase. Therefore, we pooled the data of 3 independently performed post-marketing surveillance studies (PMSs, 2 studies with 309 and 107 CD patients, respectively, and 1 study with 659 RA patients), amounting to a total number of 1,075 patients treated at 255 study sites. All PMSs were designed as prospective non-experimental and non-controlled multicenter observational studies…

Schlagworte

Crohn's disease Infliximab TNF-alpha post marketing surveillance rheumatoid arthritis safety profile Zeitschrift für Gastroenterologie